Poolbeg Pharma PLC Announces Change of Registered Address

Change of registered address

LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM: POLB) (OTCQB: POLBF), (“Poolbeg” or the “Company”), a biopharmaceutical company focused on the development and commercialization of innovative medicines targeting diseases with high unmet medical need, announces that the Company has changed its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.

Ask for information

Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, Chief Financial Officer	+44 (0) 207 183 1499
Cavendish Capital Markets Ltd (designated advisor and joint dealer) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)	+44 (0) 207 220 0500
Shore Capital Stockbrokers Ltd (joint broker) David Coaten, Harry Davies-Ball (business consultancy), Malachy McEntyre, Isobel Jones (business brokerage)	+44 (0) 207 408 4090
J&E Davy (joint broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Optimal strategic communications Nick Bastin, Vici Rabbetts, Elena Bates	+44 (0) 208 078 4357 [email protected]

About Poolbeg Pharma
Poolbeg Pharma plc is engaged in the development and commercialization of innovative medicines targeting diseases with high unmet medical need, with an increasing focus on rare and orphan diseases. Its model focuses on the development of its promising clinical assets and the commercialization of approved and marketed medicines to support the growth of the company and the development of its strong pipeline of innovative products, thereby generating significant value creation.

Poolbeg is led by an experienced management team, with a proven track record of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc management team, with the intention of repeating Amryt’s success and generating revenue in the near term.

Poolbeg’s clinical programs target broad addressable markets including cancer immunotherapy-related Reynolds syndrome, infectious diseases and metabolic disorders such as obesity, with the development of an oral GLP-1R agonist. The company uses a cost-effective development philosophy to generate high-quality human data to support partnership and further development. Its AI-driven infectious disease programs analyze unique data from human clinical trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

For more information, visit www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

This information is provided by RNS, the information service of the London Stock Exchange. RNS is authorised by the Financial Conduct Authority to act as a provider of primary information in the United Kingdom. Terms and conditions relating to the use and dissemination of this information may apply. For further information please contact [email protected] or visit www.rns.com.

SOURCE: Poolbeg Pharma PLC

View the original press release on accesswire.com